Effect of fexofenadine hydrochloride on allergic rhinitis aggravated by air pollutants. Issue 2 (6th April 2021)
- Record Type:
- Journal Article
- Title:
- Effect of fexofenadine hydrochloride on allergic rhinitis aggravated by air pollutants. Issue 2 (6th April 2021)
- Main Title:
- Effect of fexofenadine hydrochloride on allergic rhinitis aggravated by air pollutants
- Authors:
- Ellis, Anne K.
Murrieta-Aguttes, Margarita
Furey, Sandy
Picard, Pascaline
Carlsten, Christopher - Abstract:
- In recent decades, seasonal allergic rhinitis (SAR) prevalence has increased and recent studies have shown that air pollutants, such as diesel exhaust particles (DEP), can increase inflammatory and allergic biomarkers. The aim of this study was to investigate the effects of DEP on SAR symptoms induced by ragweed and to evaluate the efficacy and safety of fexofenadine HCl 180 mg versus placebo. This phase 3, single-centre, sequential, parallel-group, double-blind, randomised study (NCT03664882) was conducted in an environmental exposure unit (EEU) during sequential exposures: Period 1 (ragweed pollen alone), Period 2 (ragweed pollen+DEP), and Period 3 (ragweed pollen+DEP+single-dose fexofenadine HCl 180 mg or placebo). Efficacy and safety were evaluated in Period 3. Primary endpoints were the area under the curve (AUC) of total nasal symptom score (TNSS) from baseline to hour 12 (AUC0–12 ) during Period 1 and Period 2; and the AUC of the TNSS from hour 2 to 12 (AUC2–12 ) during Period 3. 251 out of 257 evaluable subjects were included in the modified intent-to-treat population. Least squares mean difference (95% CI) for TNSS Log AUC0−12 in Period 2 versus Period 1 was 0.13 (0.081–0.182; p<0.0001). Least squares mean difference in TNSS Log AUC2−12 for fexofenadine HCl versus placebo during Period 3 was −0.24 (−0.425–−0.047; p=0.0148). One fexofenadine HCl-related adverse event was observed. SAR symptoms evoked by ragweed were aggravated by DEP. Fexofenadine HCl 180 mg wasIn recent decades, seasonal allergic rhinitis (SAR) prevalence has increased and recent studies have shown that air pollutants, such as diesel exhaust particles (DEP), can increase inflammatory and allergic biomarkers. The aim of this study was to investigate the effects of DEP on SAR symptoms induced by ragweed and to evaluate the efficacy and safety of fexofenadine HCl 180 mg versus placebo. This phase 3, single-centre, sequential, parallel-group, double-blind, randomised study (NCT03664882) was conducted in an environmental exposure unit (EEU) during sequential exposures: Period 1 (ragweed pollen alone), Period 2 (ragweed pollen+DEP), and Period 3 (ragweed pollen+DEP+single-dose fexofenadine HCl 180 mg or placebo). Efficacy and safety were evaluated in Period 3. Primary endpoints were the area under the curve (AUC) of total nasal symptom score (TNSS) from baseline to hour 12 (AUC0–12 ) during Period 1 and Period 2; and the AUC of the TNSS from hour 2 to 12 (AUC2–12 ) during Period 3. 251 out of 257 evaluable subjects were included in the modified intent-to-treat population. Least squares mean difference (95% CI) for TNSS Log AUC0−12 in Period 2 versus Period 1 was 0.13 (0.081–0.182; p<0.0001). Least squares mean difference in TNSS Log AUC2−12 for fexofenadine HCl versus placebo during Period 3 was −0.24 (−0.425–−0.047; p=0.0148). One fexofenadine HCl-related adverse event was observed. SAR symptoms evoked by ragweed were aggravated by DEP. Fexofenadine HCl 180 mg was effective in relieving pollen-induced, air pollution-aggravated allergic rhinitis symptoms. This is the first randomised, double-blind, large study to demonstrate the beneficial effect of a histamine H1-receptor antagonist by reducing ragweed pollen-induced seasonal allergic rhinitis symptoms aggravated by controlled exposure to air pollutants https://bit.ly/3oauMFu … (more)
- Is Part Of:
- ERJ open research. Volume 7:Issue 2(2021)
- Journal:
- ERJ open research
- Issue:
- Volume 7:Issue 2(2021)
- Issue Display:
- Volume 7, Issue 2 (2021)
- Year:
- 2021
- Volume:
- 7
- Issue:
- 2
- Issue Sort Value:
- 2021-0007-0002-0000
- Page Start:
- Page End:
- Publication Date:
- 2021-04-06
- Subjects:
- Respiratory organs -- Diseases -- Periodicals
Respiration -- Periodicals
Respiration
Respiratory organs -- Diseases
Respiratory organs -- Diseases -- Treatment
Respiratory Tract Diseases
Electronic journals
Fulltext
Internet Resources
Periodicals
Periodical
616.2005 - Journal URLs:
- http://openres.ersjournals.com/ ↗
http://bibpurl.oclc.org/web/76947 ↗ - DOI:
- 10.1183/23120541.00806-2020 ↗
- Languages:
- English
- ISSNs:
- 2312-0541
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library HMNTS - ELD Digital store
- Ingest File:
- 24873.xml